Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,789 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention 2 - Sham Treatment Clear all

Conditions: COPD, Emphysema or COPD, Chronic Bronchitis
Interventions: Treatment Then Placebo, Placebo Then Treatment; Procedure
Lead sponsor: Lung Institute; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Atrial Fibrillation
Interventions: Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux), Placebo (for warfarin), Avidin, Placebo (for avidin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 3,773 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 162
States / cities: Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more

Conditions: Marijuana Use Disorder
Interventions: Inactive Marijuana (0% THC), Low THC marijuana (1.8 %THC), High THC marijuana (3.9% THC); Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Prematurity, Development Delay, Premature Birth
Interventions: Recorded Maternal Voice, Placebo Recording; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 28 Weeks to 33 Weeks
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Disease, Retinitis, Vision Tunnel, Vision Disorders
Interventions: QR-1123, Sham procedure; Drug · Other
Lead sponsor: ProQR Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Aurora, Colorado • Gainesville, Florida • Lexington, Kentucky + 2 more

Conditions: Migraine, Aura, Patent Foramen Ovale
Interventions: BioSTAR Septal Repair Implant System, Sham Procedure; Device · Procedure
Lead sponsor: NMT Medical; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Stamford, Connecticut • Seattle, Washington

Conditions: Coronary Artery Disease, Angina Pectoris
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 2,651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 86
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 74 more

Conditions: Autism
Interventions: Video Modeling Intervention, Placebo Video; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Months to 36 Months
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Coronary Artery Disease
Interventions: Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin; Drug
Lead sponsor: Baim Institute for Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 25,682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 178
States / cities: Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more

Conditions: BPH With Symptomatic Lower Urinary Tract Symptoms
Interventions: ProVee Urethral Expander System, Urethral Access Sheath; Device · Procedure
Lead sponsor: ProVerum Medical; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 221 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 14
States / cities: Sacramento, California • Hialeah, Florida • Palm Coast, Florida + 10 more

Conditions: Prediabetes, Type 2 Diabetes (T2DM)
Interventions: Vitamin D (Cholecalciferol ), Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 30 Years to 74 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Kidney Disease
Interventions: AZD4248, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Glendale, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more

Conditions: Chronic Low Back Pain, Type 2 Diabetes Mellitus
Interventions: Osteopathic Manual Treatment (OMT), Sham OMT; Other
Lead sponsor: University of North Texas Health Science Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC); Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypertension
Interventions: Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress; Drug · Dietary Supplement · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pulmonary Hypertension
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Milk Allergy
Interventions: Placebo for omalizumab, Omalizumab, Milk powder; Biological · Drug
Lead sponsor: Hugh A Sampson, MD; Other
Eligibility: 7 Years to 35 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Stanford, California • Baltimore, Maryland • New York, New York

Conditions: Speech
Interventions: TMS, somatosensory acuity measurement; Device · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Patellar Tendinitis
Interventions: PRP, Dry Needling, Dry Needling - Sham; Biological · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 39 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Myocardial Infarction
Interventions: abciximab placebo; reteplase placebo, abciximab, abciximab, Abciximab; reteplase; abciximab placebo; abciximab, abciximab; reteplase placebo; abciximab placebo; abciximab; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 2,461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 52
States / cities: Phoenix, Arizona • Covina, California • Modesto, California + 49 more

Conditions: Hypotension
Interventions: Sodium chloride, Fentanyl; Drug
Lead sponsor: Loyola University; Other
Eligibility: 60 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Aging, Depression, Cognitive Symptoms
Interventions: Depression Cognitive Training, Non-Specific Cognitive Training, tDCS (active stimulation), tDCS (sham stimulation); Behavioral · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Suicidal Ideas
Interventions: Alcohol administration, Placebo administration, Positive mood induction, Negative mood induction; Other · Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cocaine Use Disorder
Interventions: Extended-Release Naltrexone, Extended Release Buprenorphine, Placebo (PLB) Injectable matched to XR-NTX, Placebo (PLB) Injectable matched to XR-BUP; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 12
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 8 more

Search by objective public record fields.

Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks

Maternal Voice and Quantitative EEG (qEEG)

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene

MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

The Effects of Video Modeling of Audiological Testing on Pediatric Patient Compliance

The Dual Antiplatelet Therapy Study (DAPT Study)

ProVee Urethral Expander System IDE Study (ProVIDE)

Vitamin D and Type 2 Diabetes - Treat-To-Target

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort

OMT of Somatic Dysfunction and Chronic Low Back Pain in Patients With Type 2 Diabetes Mellitus

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

Treatment of Supine Hypertension in Autonomic Failure

Targeting the Right Ventricle in Pulmonary Hypertension

OIT and Xolair® (Omalizumab) in Cow's Milk Allergy

Modulation of Sensory Acuity With Transcranial Magnetic Stimulation (TMS)

Platelet-Rich Plasma Therapy for Patellar Tendinopathy

A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)

Fentanyl Effect on Blood Pressure in Elderly Patients After Induction of General Anesthesia

Cognitive Enhancement in Recurrent Depression (The COG-D-R Study)

Effects of Alcohol and Mood on Attention

Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)